Icecure Medical Ltd
icecure-medical.comWhat Do They Do?
Sells disposable probes and freezing-based systems for treating tumors and nerves to medical providers and distributors.
20-F for FY2025, filed Mar 17, 2026
How Do They Make Money?
Customers buy disposable probes and cryoablation systems; product sales are counted when shipped or delivered. Maintenance and other service agreements bring in revenue over the contract term.
20-F for FY2025, filed Mar 17, 2026The Company’s revenues are derived primarily from the sale of systems and disposables. Revenues from warranty and services are not material…View ↗
Revenues from product sales are recognized upon the transfer of control, which is generally upon shipment or delivery.View ↗
For maintenance agreements that provide service beyond the Company’s standard warranty and other service agreements, revenue is recognized…View ↗
-
20-F for FY2025, filed Mar 17, 2026
FY2025 revenue by product or service ↗
$3.4M
-
20-F for FY2025, filed Mar 17, 2026
$3.4M ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Systems
Sold outright
20-F for FY2025, filed Mar 17, 2026 |
39%
FY2022: 32%
|
Systems, FY2025
$1.3M Sources
|
Sold outright |
|
Disposables
Sold outright
20-F for FY2025, filed Mar 17, 2026 |
61%
FY2022: 43%
|
Disposables, FY2025
$2.1M Sources
|
Sold outright |
Who Are Their Customers?
It sells systems and disposables to distributors and end users; in China it sells through Beijing Turing, which imports the products and resells them to Shanghai Medtronic Zhikang.
20-F for FY2022, filed Mar 29, 2023 20-F for FY2025, filed Mar 17, 2026
Do Revenues Turn Into Profits?
No. It lost $15.1M in FY2025.
20-F for FY2025, filed Mar 17, 2026
−$15.1MView ↗
20-F for FY2025, filed Mar 17, 2026
−$15.1MView ↗
20-F for FY2025, filed Mar 17, 2026
−$14.6MView ↗
How Are They Changing?
Shrinking. Revenue fell 18% in 4 years, from $4.1M in FY2021 to $3.4M in FY2025, about 5% a year.
Breast-cancer treatment
The latest report says ProSense is authorized for low-risk breast cancer in women receiving adjuvant endocrine therapy; the older report said the company had not received approval for malignant breast tumors.
20-F for FY2022, filed Mar 29, 2023 20-F for FY2025, filed Mar 17, 2026We believe that obtaining regulatory approval for our existing and next generation products for specific indications will help us grow our…View ↗
We are a commercial stage medical device company focusing on the research and development of cryoablation systems, disposables based on LN2…View ↗
Broader treatment uses
The latest report also describes using cryoablation for nerve ablation and conditions such as endometriosis, while the older report described tumor treatment.
20-F for FY2022, filed Mar 29, 2023 20-F for FY2025, filed Mar 17, 2026We are a commercial stage medical device company focusing on the research, development and marketing of cryoablation systems, disposables…View ↗
We are a commercial stage medical device company focusing on the research and development of cryoablation systems, disposables based on LN2…View ↗
Who Do They Compete With?
Competes with Sanarus Medical, Galil Medical, EndoCare, Hygea Medical Technology, and Beijing Sunshine Yibang Medical Technology
20-F for FY2025, filed Mar 17, 2026We believe that our direct competitors for cryoablation of malignant breast tumors are Sanarus Medical, Inc. which is part of Hologic Inc.…View ↗
Loading...
